New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC)

The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model has been validated for patients (pts) with mRCC in the second line TT setting. This model does not consider time from 1st to 2nd line therapy, tumor shrinkage during 1st line and tumor burden before 2nd line. We sought to investigate these factors in addition to IMDC ones.09/26/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news